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Background. Spinal myxopapillary ependymomas (MPEs) are slowly growing ependymal gliomas with preferential manifestation in
young adults. The aim of this study was to assess the outcome of patients with MPE treated with surgery, radiotherapy (RT), and/
or chemotherapy.
Methods. The medical records of 183 MPE patients (male: 59%) treated at the MD Anderson Cancer Center and 11 institutions from the
Rare Cancer Network were retrospectively reviewed. Mean patient’ age at diagnosis was 35.5+15.8 years. Ninety-seven (53.0%) pa-
tients underwent surgery without RT, and 86 (47.0%) were treated with surgery and/or RT. Median RT dose was 50.4 Gy. Median follow-
up was 83.9 months.
Results. Fifteen (8.2%) patients died, 7 of unrelated cause. The estimated 10-year overall survival was 92.4% (95% CI: 87.7–97.1).
Treatment failure was observed in 58 (31.7%) patients. Local failure, distant spinal relapse, and brain failure were observed in 49
(26.8%), 17 (9.3%), and 11 (6.0%) patients, respectively. The estimated 10-year progression-free survival was 61.2% (95% CI:
52.8–69.6). Age (,36 vs ≥36 y), treatment modality (surgery alone vs surgery and RT), and extent of surgery were prognostic factors
for local control and progression-free survival on univariate and multivariate analysis.
Conclusions. In this series, treatment failure of MPE occurred in approximately one third of patients. The observed recurrence pattern of
primary spinal MPE was mainly local, but a substantial number of patients failed nonlocally. Younger patients and those not treated
initially with adjuvant RT or not undergoing gross total resection were significantly more likely to present with tumor recurrence/
progression.
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Myxopapillary ependymoma (MPE) is classified as a World Health
Organization (WHO) grade I glioma, located almost exclusively in
the region of the conus medullaris, cauda equina, and filum
terminale of the spinal cord. Less than 5% of MPEs occur in
sites outside the lumbar thecal sac. This tumor, with an incidence
of 0.05–0.08 per 100 000 persons per year,1 is characterized by a
papillary arrangement of cuboidal tumor cells around a vascular
stromal core that undergoes mucinous degeneration. MPE arises
from the ependymal lining of the spinal canal and can be infre-
quently observed in the brain parenchyma2 or lateral ventricle.3
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Anaplastic variants are virtually unknown.1 Young adults (18–29 y)
are usually affected, and 8%–20% of all MPEs occur in the pedi-
atric population.4 –7 It is believed to be a slowly growing ependymal
glioma, thus with a favorable prognosis, which can, however, occa-
sionally exhibit elevated mouse intestinal bacteria 1 labeling indi-
ces.8 Seeding of the subarachnoid space8 and extraneural
metastasis9,10 can take place, and the outcome of MPE is thus
not universally favorable for all MPE patients. Patient’ age, extent
of surgery, and tumor size have been identified as major prognos-
ticators for this tumor entity in 2 large retrospective studies.11,12
Notwithstanding the favorable outcome assumed in the neuro-
surgical cognoscenti, we assessed the outcome and pattern of fail-
ures of spinal MPE using the 2 largest databases published. These 2
identical datasets were merged, updated, and expanded with new
MPE cases to address more fully the prognostic factors of this rare
tumor entity with a debatable good prognosis.
Patients and Methods
The Rare Cancer Network (RCN; http://www.rarecancer.net) is a
multi-institutional cooperative group created to initiate large ret-
rospective studies of rare cancers to improve our knowledge of
their treatment outcomes and prognostic factors. The computer-
ized database, based at Geneva University Hospital, which initiat-
ed the first RCN analysis of the primary spinal MPE cohort,12 was
purposely identical to the one created previously at the MD An-
derson Cancer Center (MDACC).11 The present study strategy
was to merge the 2 databases in order to update the follow-up pe-
riod of patients and add new patients managed at the MDACC or
one of the RCN institutions. The institutional databases were que-
ried and 183 patients with spinal MPE were identified during a
44-year period (January 1968–March 2012). The inclusion criteria
were histology-proven MPE (WHO grade I; International Classifica-
tion of Diseases for Oncology M-9394/1), with only primary spinal
localization. Mixed tumors (with a minor WHO grade II compo-
nent) were also included. In this study, all investigators obtained
their own institutional review board approvals for patients’ data
collection. The updated data were resubmitted electronically to
the principal investigator (D.C.W.) at Geneva University Hospital.
Follow-up data of varying duration were available for all patients
in this study. The median follow-up period of the surviving patients
was 60.0 months (range, 0.2–316.6).
Patient Characteristics
Patient characteristics are detailed in Table 1. The majority
(.60%) of patients presented with MPE localized to the lumbosa-
cral spine or cauda equina (Table 1). All but 4 (2.2%) patients had
nonmetastatic disease at diagnosis. Two patients presented with
supratentorial brain and spinal metastases and another 2 pa-
tients presented with spinal metastases at diagnosis. One
(0.5%) patient presented with a synchronous temporoparietal oli-
godendroglioma. Seven (3.8%) patients had MPE mixed with
WHO grade II ependymoma.
No central histopathologic review by an expert pathologist was
performed. The most common presenting symptom was low-
back pain (Table 1). Neurological function was evaluated by the
Frankel classification system (ranging from normal motor func-
tion [grade E] to complete neurological injury [grade A]).13 Grad-
ing was performed before surgery and during last follow-up visits.
Complete motor or sensory loss of function was rare (3.4%;
Table 1), but numbness of the extremities was frequent (47.8%;
Table 1). Bladder sphincter dysfunction occurred in 30% of pa-
tients (Table 1). Spinal lesions were identified with MRI in a major-
ity of patients (n¼ 150). MRI was interpreted as abnormal in all
cases. Noteworthy, no central radiological review was performed
for this study. Other imaging modalities were CT scan (n¼ 35)
and myelography (n¼ 31). All myelographies were interpreted
as abnormal, but 2/35 CT scans were considered normal at the
time of diagnosis. Tumor size was available for 86 (47%) patients.
Largest dimension (radiology and/or operative notes) of MPE
ranged from 1.0 to 200.0 mm (median, 20.0).
Therapy
Surgery was the initial treatment for all but one patient (radio-
therapy [RT] alone, n¼ 1; Table 1). Initial treatment modality of
Table 1. Patient characteristics and treatment details
Variable Number (%)







Grade I only (MPE) 176 (96.2)
Grades I and II 7 (3.8)
Symptoms
Low-back pain 155 (84.7)
Extremity numbness 85 (46.4)
Extremity weakness 75 (41.0)
Urinary dysfunction 54 (29.5)
Abnormal gait 37 (20.2)
85 (46.4)
Tumor location
Cervical only 1 (0.5)
Cervicothoracic 2 (1.1)
Thoracic only 1 (0.5)
Thoracolumbar 58 (31.7)
Lumbosacral/filum terminale 121 (66.2)




Surgery alone 96 (52.6)
Surgery and radiotherapy 85 (46.4)
Surgery and chemotherapy 1 (0.5)
RT alone 1 (0.5)
Extent of surgery
Gross total resection 99 (54.1)
Subtotal resection 73 (39.9)
Biopsy only 6 (3.3)
Unknown 5 (2.7)
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these patients was surgery alone, with (n¼ 1) or without chemo-
therapy (n¼ 96), and surgery with pre- and postoperative RT in 97
(53.0%) and 85 (46.4%) patients, respectively.
The extent of surgery was determined from the surgical notes
and/or postoperative imaging studies. Gross total removal (GTR)
was defined as complete resection of the MPE by the surgeon
or by the absence of residual tumor on postoperative CT/MRI
scans. Subtotal removal was performed if the surgeon observed
unresected MPE in the tumor bed or if residual tumor was identi-
fied on postoperative imaging studies. The extent of surgery is de-
tailed in Table 1. Six patients underwent biopsy only (Table 1).
All RT patients were treated with megavoltage photon beams.
The median overall treatment time of RT was 37 days (range, 17–
59). Median administered dose was 50.4 Gy and ranged from 25.2
to 60.0 Gy. A median of 28 fractions (range, 14–40) of 1.0–2.3 Gy
(median, 1.8) were delivered. The RT volume was usually the pri-
mary tumor plus one vertebral body above and below the verte-
bral level affected by the MPE. This treatment technique was
described as focal RT (n¼ 45 patients). Thirty other patients
were treated with focal RT with unspecified margins. Craniospinal
irradiation with and without a focal boost was delivered to 3 and
1 patient, respectively. The treatment volume was unknown for 6
patients.
Statistical analysis
Progression-free survival (PFS) and overall survival (OS) were cal-
culated from the date of surgery using Kaplan–Meier estimates.
The events were death (all causes included) for OS and progres-
sive disease or death for PFS. Progressive disease was defined as
any treatment failure occurring locally (initial spinal involvement)
and/or distantly (spine and/or brain). We used a 2-tailed t-test to
compare clinical or therapeutic covariates. For frequency analysis,
we used Fisher’s exact test for 2-way tables. Differences between
groups were assessed using the log-rank test.14 The log-rank test
was used to compare different survival functions according to
various clinical factors (age, gender, tumor location, tumor vol-
ume, metastasis at diagnosis, and laterality of symptoms) and
therapeutic factors (initial treatment modality, extent of surgery).
Multivariate analysis was performed using Cox stepwise regres-
sion analysis to define the independent contribution of each prog-
nostic factor.15 Clinical and therapeutic factors shown to be either
significant or potentially relevant (P≤ .1) in the univariate analysis
were forced in the Cox model. Statistical tests were based on a
2-sided significance level, and a P-value of .05 or less was consid-
ered to be statistically significant. Statistical analysis was per-
formed on Statistical Package for Social Sciences version 18.0.
Results
Patient Outcomes
At the time of the analysis, 15 (8.2%) patients had died, 8 (53.3%)
from tumor progression. The estimated 10-year OS was 92.4%
(95% CI: 87.7–97.1).
Fifty-eight (31.7%) patients experienced treatment failure.
Median time to treatment failure was 26.5 months (range, 1.7–
177.4). The estimated 5- and 10-year PFS rates were 69.5% (95%
CI: 61.9 –77.1) and 61.2% (95% CI: 52.8 –69.6), respectively
(Fig. 1). Local recurrence was observed in a majority (49/58;
84.5%) of patients with treatment failure. Among patients recur-
ring locally, 37 presented with local failure only. Local and distant
spinal failures were observed in 6 patients; 2 patients had com-
bined local and brain failures. Four other patients presented
with local, distant spinal, and brain concomitant failure. A sub-
stantial number of patients (n¼ 11; 19.0% of all tumor progres-
sion) presented with brain failures (Table 2). Brain failure only was
observed in 2 patients, while in 3 patients concomitant distant
spinal failure was observed. Distant spinal failure only was ob-
served in 4 patients. No extraneural metastasis was observed.
Table 2 details the pattern of tumor progression. The estimated
Table 2. Pattern of treatment failure in 183 MPE patients
Type of Treatment Failure Number of Patients %a
Local 49 84.5
Local only 37 63.8
Local and distant spinal 6 10.3
Local and brain 2 3.4
Local, brain, and distant spinal 4 6.8
Brain 11 19.0
Brain only 2 3.4
Brain and local 2 3.4
Brain and distant spinal 3 5.2
Brain, local, and distant spinal 4 6.8
Distant spinal 17 29.3
Distant spinal only 4 6.8
Distant spinal and local 6 10.3
Distant spinal and brain 3 5.2
Distant spinal, local, and brain 4 6.8
aDue to the ratio approximations, percentages may not exactly add.
Fig. 1. Progression-free survival for 183 MPE patients.
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5- and 10-year local failure-free and brain-failure-free survivals
were 73.2% (95% CI: 65.9–80.5)–66.8% (95% CI: 58.6–75.0)
and 93.9% (95% CI: 90.0–97.8) –92.8% (95% CI: 88.3–97.3),
respectively.
Of the 58 patients with treatment failure, the majority (48/58;
82.8%) underwent salvage treatment. Patients were salvaged
with surgery alone (n¼ 14), surgery and RT (n¼ 13), focal RT
(n¼ 11), surgery with RT and chemotherapy (n¼ 3), chemother-
apy only (n¼ 3), extensive spinal RT (n¼ 2), whole brain RT with
distant spinal RT (n¼ 1), and surgery for local recurrence with cra-
niospinal RT for distant spinal relapse (n¼ 1). No salvage treat-
ment was offered to 10 (17.2%) patients. Overall, the 5- and
10-year OS rates for recurring and nonrecurring patients were
90.3% (95% CI: 82.3 –98.3) –88.1% (95% CI: 79.1 –97.1) and
97.2% (95% CI: 94.1–100.0)–94.9% (95% CI: 89.6–100.0), re-
spectively (P¼ .32).
Acute and Late Adverse Effects
Acute toxicity occurred in 19 (10.4%) patients. The most frequent
acute toxicity was skin erythema and nausea. Grades I, II, and III
adverse events of the Common Terminology Criteria for Adverse
Events (CTCAE v3; http://ctep.cancer.gov/protocolDevelopment/
electronic_applications/docs/ctcaev3.pdf) were observed in 6,
11, and 1 patient, respectively. One patient presented posttreat-
ment intestinal perforation and peritonitis (CTCAE grade 5).
Late adverse events were observed in 42 (23.0%) patients. Re-
ported during follow-up were chronic pain (n¼ 8), motor paraple-
gia (n¼ 5), hypoesthesia (n¼ 4), urinary sphincter dysfunction
(n¼ 2), urinary sphincter dysfunction and paraplegia (n¼ 2),
bowel sphincter dysfunction (n¼ 1), scoliosis (n¼ 1), ataxia (n¼
1), subcutaneous fibrosis (n¼ 1), and amenorrhea (n¼ 1). Late
adverse events were unknown in 16 patients. Of note, no
radiation-induced myelopathy was observed among patients
treated with surgery+ RT. The 5- and 10-year probabilities of
complication-free survival were 80.5% (95% CI: 73.6–87.4) and
72.6% (95% CI: 64.0–81.2), respectively. There was a statistical
trend toward significance for treatment modality and late ad-
verse events: patients treated with surgery alone had usually
less late toxicity compared with those treated with surgery+ RT
(43.9% vs 56.1%; P¼ .07). No other clinical factors (gender, P¼
.21; age, P¼ .80; tumor location, P¼ .84; tumor size, P¼ .25) or
therapeutic factors (total dose, P¼ .86; extent of resection, P¼
.42) were predictive of late adverse events.
Secondary cancers were observed in 6 (3.3%) patients, 0.2–
16.0 years (median, 4.2) after treatment. Three (50%) patients
were treated initially for their MPE with surgery alone, and 3
other (50%) patients were treated with surgery and postoperative
RT. In these, all but 1 tumor occurred in the treatment field and
were thus possibly radiation induced (total, n¼ 2/6). All patients
with secondary tumors were alive at last follow-up. No clinical
factors (gender, P¼ .24; age, P¼ .44; tumor location, P¼ .99;
tumor size, P¼ .99) or therapeutic factors (treatment moda-
lity, P¼ 1.0; total dose, P¼ .5; RT volume, P¼ .52; type of RT,
P¼ 1.0) were predictive of secondary tumors. The survival be-
tween patients with and without secondary tumors was not sig-
nificantly different: the estimated 5-year OS was 94.4% (95% CI:
90.7–98.1) and 100% for patients with and without secondary
cancers, respectively (P¼ .51).
Prognostic Factors for OS and PFS
The influence on local control, PFS, and OS of both clinical and
treatment variables was examined. Table 3 details the results of
the univariate analysis. Local control and PFS were negatively in-
fluenced (Table 3) by younger age (,36 y) and initial surgery with-
out RT (Fig. 2). The extent of surgery was also a significant
detrimental factor for local control and PFS (Table 3). Metastasis
at diagnosis negatively influenced PFS and OS (Table 3). Patients
undergoing salvage therapy were significantly more controlled lo-
cally (Table 3). There were no statistically significant associations
between gender, tumor location, tumor size, or laterality of symp-
toms on local control, PFS, or OS rates (Table 3).
Multivariable Cox proportional hazards models were used to
examine factors associated with local control, PFS, and OS while
controlling for potential confounders. Only age, treatment modal-
ity, and extent of surgery remained independent predictors of
local control and PFS (Table 4). Interestingly, the hazard ratios
for local control and PFS were 0.34 and 0.28 for adjuvant low-
dose and high-dose RT, respectively (Table 4). On multivariate
analysis, no independent factors were associated with OS.
Discussion
To the best of our knowledge, the present series is the largest
study published on spinal MPE and raises several key issues that
should have a substantial impact on present therapeutic ap-
proaches for this tumor entity.
First, young age was a significant detrimental independent
predictor for MPE patient’ outcome, be it on local, distant spinal,
or brain control (Table 4). The survivorship of younger patients
was, however, better, although the difference was not statistically
significant (Table 4). This may be due to the fact that MPE may not
substantially impact the survivorship of young and healthy indi-
viduals with no comorbidities. Likewise, the survival of nonsal-
vaged patients in this series was not significantly different than
that of salvaged patients, suggesting that MPE produces substan-
tial impairment but does not critically reduce survival. This finding
was reported by the MDACC group11 and subsequently by the RCN
institutions.12 In the pediatric population, the reported MPE’
behavior is all but benign. Fassett and colleagues9 reported on
26 children with MPE (mean age, 11+2.9 y) treated with surgery,
with and without RT.9 In those cases in which patients underwent
spinal screening at diagnosis, a majority (58.3%) presented with
disseminated spinal disease. A high incidence of tumor dissemi-
nation has also been observed in adult and pediatric MPE.16 The
reported event-free survival was only 50% in another small MPE
pediatric series, compared with 100% for spinal ependymoma.4
These data are in line with the seminal paper stemming from
the Mayo group, showing that recurrences were frequently ob-
served in younger patients.6 Conversely, age was not a prognos-
ticator in a small series encompassing spinal ependymomas and
MPEs in adult and pediatric patients (mean age, 37 y; range, 8–
66), although all patients received postoperative RT, and the im-
pact of age was not reported specifically for the MPE variant.17 In
our series, three quarters of all patients with metastatic cases at
presentation were younger than 36 years (mean, 16.2+3.9 y;
data not shown). Although spinal dissemination at diagnosis is
rare in adults (Table 1), we recommend that all patients undergo
brain and spinal MRI and CSF cytology in their initial workups
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before initiation of treatment. Moreover, the 10-year PFS in our se-
ries was 40% for younger patients, compared with 85% for
older patients. As such, the former cohort should be treated ag-
gressively with adjuvant RT, when complete resection has not
been obtained by the surgeon. A recent series has shown that
local control rates were 30% and 100% for pediatric patients
treated with surgery alone and surgery with adjuvant RT,
respectively.18
Second, adjuvant RT increased 10-year PFS from ,40% to
70% in patients receiving this modality, compared with those
not treated with postoperative radiation (Table 3). This would jus-
tify more liberal use of adjuvant RT, especially in those patients
with subtotal resection and piecemeal resection, or questionable
GTR in patients with spinal MPE. Immediate RT following resection
is an accepted standard treatment for intracranial ependymomas,
as a result of several retrospective studies showing a benefit of
postoperative RT over surgery alone.19 – 22 Adjuvant radiation for
MPE has been questioned, especially for children, as a result of
its presumed benign nature (WHO grade I). It can be counter-
argued (i) that complete resection of tumor is not common, occur-
ring in approximately 1 patient out of 2 (Table 1), as observed in
other series,6,11,12 and (ii) that, given time, tumor progression
with spinal and/or brain dissemination will occur. MPE produces a
myxoid matrix material that may render GTR chiefly challenging,
particularly so in the filum terminale. As such, radiation may con-
trol these tumor cells, due to the known radiosensitivity of ependy-
mal cells,23 and RT is consequently the mainstay in pursuing this
aim. Although late recurrence was observed in this series, the me-
dian time to treatment failure was 2 years, suggesting that the
benefit of RT may not be restricted to younger patients with longer
Table 3. Univariate analysis for local control, PFS, and OS
Parameters Cumulative Proportion of
Patients With Local Tumor
Control (SE)
P Cumulative Proportion of Patients
With Local and Distant Tumor
Control (SE)
P Cumulative Proportion of
Surviving Patients (SE)
P
Age, y ,.001 ,.001 .11
,36 0.40 (0.06) 0.30 (0.06) 0.86 (0.07)
≥36 0.84 (0.05) 0.81 (0.05) 0.64 (0.12)
Gender .22 .29 .26
Female 0.68 (0.06) 0.59 (0.07) 0.96 (0.03)
Male 0.56 (0.06) 0.50 (0.06) 0.89 (0.05)
Tumor location .66 .58 .46
Lumbosacral/filum
terminale
0.68 (0.04) 0.53 (0.05) 0.75 (0.07)
Cervicothoracic 0.75 (0.21) 0.75 (0.21) 1.0
Metastasis at diagnosis .28 .03 .03
No 0.77 (0.07) 0.54 (0.05) 0.77 (0.07)
Yes 0.50 (0.21) 0.66 (0.20) 0.50 (0.30)
Tumor size .28 .35
,20 mm 0.59 (0.11) 0.52 (0.11) 1.0 .17
≥20 mm 0.80 (0.07) 0.58 (0.12) 0.89 (0.07)
Symptoms .20 .52 .16
Unilateral 0.36 (0.25) 0.30 (0.22) 0.93 (0.04)




Surgery alone 0.45 (0.08) 0.38 (0.08) 0.92 (0.03)
Surgery and
standard-dose RTb
0.71 (0.08) 0.56 (0.08) 0.86 (0.06)
Surgery and
high-dose RTc
0.66 (0.10) 0.66 (0.11) 0.71 (0.15)
Extent of surgery .02 .02 .10
GTR 0.68 (0.06) 0.63 (0.07) 0.90 (0.04)
STR or biopsy 0.55 (0.06) 0.45 (0.06) 0.70 (0.10)
Salvage treatment ,.001 .86 .87
Yes 0.03 (0.02) 0.02 (0.02) 0.74 (0.09)
No 0.55 (0.06) 0.11 (0.10) 0.88 (0.10)
Abbreviation: STR, subtotal removal.
aSurgery vs surgery+ standard-/high-dose RT.
b,50.4 Gy.
c≥50.4 Gy.
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life expectancies, who have a longer time horizon to experience
tumor progression or recurrence.
Third, the role of surgery is of paramount importance for this
tumor entity. GTR has been shown to be the most important
prognosticator for ependymoma patients. As discussed, GTR for
MPE, unlike ependymoma, with low neurological disability, can in-
frequently be accomplished, but the extent of resection is indeed
also of paramount importance for this ependymal variant. In the
Mayo study, the risk of treatment failure was decreased from 34%
to 10%.6 We have also observed a significant (P¼ .01) decrease
of treatment failure with GTR (Table 4).
Fourth, although the observed recurrence rate was substantial
(Fig. 1), the survival of MPE patients was indeed good. Interesting-
ly, salvage therapy did not improve the survivorship of recurring
patients. Only a minority of patients died of MPE, suggesting
that this tumor is indeed locally aggressive but does not have a
major impact on the survival status of MPE patients. We did ob-
serve that patients with local failures, compared with those with
distant spinal or brain failures, with or without a local component,
had better survival, although the observed difference was not sig-
nificant. Treatment failure may not have a major impact on sur-
vival but it may indeed have an impact on quality of life. Due to
the retrospective nature of this study, this metric could not be as-
sessed. Of note, patients with spinal or brain failures, with or with-
out a local component, had substantially more late side effects
(16.2% vs 23.8%), although the difference was not significantly
relevant (P¼ .19; data not shown).
Finally, it has always been assumed that MPE was more prev-
alent in male patients. The reported male/female ratio varies
from 1.4:1 to 2.5:1.11,12,24 In this larger cohort, we did observe
a gender ratio at the lower published range, suggesting that
this tumor is more gender neutral than previously assumed.
Concerns regarding long-term radiation-induced toxicity have
been made by patients, parents, and caregivers alike. We did not
observe any substantial late toxicity in patients receiving RT com-
pared with those treated with surgery only. Secondary cancers
were observed in a minority of patients, and only 2/183 (3.4%)
secondary tumors in the entire cohort may have been radiation
induced. The use of more conformal treatment, not limited to
but including proton beam therapy25 and stereotactic fractionat-
ed RT,26 may somewhat decrease this rare but feared serious ad-
verse effect.
We have observed an increase of local and distant control with
high-dose (≥50.4 Gy) as opposed to low-dose RT on univariate
analysis (Table 3). This factor was not significant in multivariate
analysis, as patients with subtotal resection usually received a
higher dose of RT (data not shown). Eleven ependymoma series
with dose responses have been published, with 6 studies showing
a beneficial effect of high-dose radiation on outcome.23 Although
the data are somewhat inconclusive, there is some suggestion of
a dose-response effect, and we would recommend administering
50.4 to 54.0 Gy to MPE patients.
Tailoring adjuvant treatment to high-risk patients only would
be most desirable, as clinical factors, such as those identified in
this study, may be too rough a prognostication tool to be clinically
Fig. 2. Progression-free survival for patients treated with surgery alone or
surgery+ RT.
Table 4. Multivariate analysis for local control (LC), PFS, and OS
Parameters Hazard Ratios for LC
(95% CI)
P Hazard Ratios for PFS
(95% CI)




,36 vs ≥36 0.21 (0.10–0.43) ,.001 0.2 (0.1–0.39) ,.001 2.56 (0.73–8.61) .13
Initial treatment modality
Surgery alone 1.0 ,.001a 1.0 ,.001a 1.0 .73
Surgery+ standard-dose RT 0.34 (0.15–0.77) 0.34 (0.16–0.71) 0.66 (0.16–2.70)
Surgery+ high-dose RT 0.28 (0.12–0.60) 0.28 (0.14–0.57) 0.55 (0.11–2.61)
Extent of surgery
GTR vs STR or biopsy 2.08 (1.13–3.82) .01 2.14 (1.38–4.24) .02 2.70 (0.76–9.52) .11
Metastasis at diagnosis
Yes vs no 1.35 (0.25–15.13) .51 1.51 (0.19–11.48) .69 6.0 (0.62–58.38) .12
Abbreviation: STR, subtotal removal.
aSurgery vs surgery+ standard-/high-dose RT.
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useful. Pathogenesis of ependymal tumors is indeed poorly un-
derstood, and molecular markers for risk-adapted patient strati-
fication are yet to be identified. Korshunov and colleagues,27 in 39
newly diagnosed ependymomas, reported a unique gene expres-
sion pattern for spinal ependymomas that distinguished those
from intracranial tumors using microarray technology. Identical-
ly, a French study using comparative genomic hybridization re-
ported that the most frequently detected chromosomal (chr)
abnormalities in spinal ependymal tumors were gain of chr 7, 9,
12, and 15.28 Losses of chr 22 were also more commonly identi-
fied in spinal tumors. The analysis of the pattern of chromosomal
imbalance in this study could also distinguish between classical
ependymomas and MPEs. MPE (n¼ 5) displayed a specific geno-
mic signature, defined by concurrent gain of chr 5, 7, 9, 16, and
18, whereas none of the other non-MPE specimens (n¼ 40) pre-
sented this genetic profile. Chromosomal changes and epigenetic
studies may well be necessary to optimally risk-stratify these
ependymal tumors. Stephen et al,4 reporting on 19 pediatric
cases (MPE, n¼ 8), reported recently no immunohistochemistry
difference between spinal ependymomas and MPEs, with the ex-
ception of EPHB3, which was usually positive in MPE. Interestingly,
this protein expression has also been reported in supratentorial
ependymomas,29 which have a more aggressive clinical course
compared with infratentorial tumors. Although a substantial num-
ber of studies have assessed the correlation between protein or gene
expression and tumor location, grade, and tumor type,4,27–29 none
have analyzed specifically the association with tumor recurrence
for a given histological subtype. A large German study reported a
gene profile of 27 genes that were associated with poor outcome
(survival ,10 y) in patients with ependymomas, but all grades
I–III were analyzed together.30 Future research regarding the
molecular prognostication of this rare ependymal tumor is justified
in the framework of collaborative studies.
This study has potential limitations inherent in all retrospective
analyses, including uncontrolled patient selection into different
treatment groups. Most importantly, the absence of central pa-
thology revision and radiological review may have included in
this cohort non-MPE histologies. This is particularly relevant for
the minority of patients with mixed histologies (Table 1). Not all
patients underwent pretreatment MRI screening for tumor dis-
semination. It remains unclear whether cases with distant spinal
or brain failures represent clinically latent disease that was pre-
sent but undetected at the time of initial presentation or ins-
tances of seeding after treatment. Additionally, the surgical
techniques have evolved during the study period, and patient’
outcome, including local control and toxicity, could be somewhat
improved in both groups of MPE patients in our series. We per-
formed multivariate analyses to control for potential confounding
factors in our examination of PFS and OS, but some residual con-
founding likely remains. Notwithstanding these legitimate reser-
vations, this series is the largest MPE study with a long follow-up
period, and the treatment strategy and techniques have been
fairly uniform among centers.
In summary, although a considerable number of patients did
present with treatment failure, OS of all MPE patients was good. A
substantial number of patients presented with nonlocal failures
(distant spinal and/or brain). Younger age, surgery alone, and
non-GTR were adverse prognostic factors for local control and
PFS. We recommend administering adjuvant high-dose RT
(≥50.4 Gy) to patients undergoing subtotal resection or biopsy.
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